Skip to content

Structure Therapeutics

US · GPCR #2815 by market cap Listed 2023
16.13 -0.99 -5.78%
Periodic snapshot; not a real-time feed. · 2026-11-20 19:30

✦ Quant Ownership Signal how this is computed

Accumulating
  • The number of reporting institutions decreased by 12 in the most recent period (2026/Q3).
  • Total institutional ownership rose 1.4 percentage points.

Ownership vs. money flow

Diverging

Institutions added shares last reporting period, and the stock has seen net outflows in main-fund flow over the last 20 trading sessions - the two are pointing in different directions.

Institutional ownership changes are reported quarterly with a lag; fund-flow data is daily. Treat this as a directional cross-check, not a precise timing signal.

Institutional ownership

Held by institutions
105.68% +1.39pp
Institutions
241 -12
As of
2026/Q3 vs. prior period

Holder types

Mutual Fund51.97%
Hedge Fund26.85%
VC/PE Fund18.30%
Public Company5.94%
Individual/Insider2.44%
Private Company1.26%
Government Pension Fund0.61%
Sovereign Wealth Fund0.60%
Insurance Company0.10%

Top holders as of 2026-09-30

FMR 12.97% · 9.25M sh
Deep Track Capital, LP 10.59% · 7.55M sh
Wellington Management Group 10.35% · 7.38M sh
Avoro Capital Advisors LLC 9.19% · 6.56M sh
Janus Henderson Group plc 7.30% · 5.20M sh
BVF Partners L.P. 4.72% · 3.37M sh
Morgan Stanley 3.95% · 2.82M sh
Morgan Stanley Investment Management Inc. 3.95% · 2.82M sh
OrbiMed Advisors LLC 3.10% · 2.21M sh
Principal Global Investors, LLC 2.46% · 1.75M sh
RTW Investments, LP 2.25% · 1.61M sh
American Century Investment Management 2.36% · 1.68M sh

Bar length is relative to the largest holder shown here, not to 100% of the company.

Insiders

50 filings tracked · 28 buys · 22 sells

NameRoleStake
FMR -- 12.97%
Jun Yoon Co- Founder, CFO & Secretary 1.25%
Raymond Stevens Chief Executive Officer 1.06%
Daniel Welch Independent Chairperson 0.06%
Xichen Lin Chief Scientific Officer & GM of Structure Shanghai 0.03%
Blai Coll Chief Medical Officer 0.02%
Yingli Ma Chief Technology Officer 0.01%
Ashley Hall Chief Development Officer 0.01%
Sharon Tetlow Independent Director --
Angus Russell Independent Director --

Insider transactions most recent Form 4 filings

DateNameRoleTypeSharesPrice
2026-09-20 Blai Coll Chief Medical Officer Other Disposition -4,008 --
2026-09-20 Blai Coll Chief Medical Officer Other Derivative Acquisition +4,008 --
2026-09-20 Blai Coll Chief Medical Officer Open Market Derivative Dispositi -4,008 --
2026-09-17 Blai Coll Chief Medical Officer Sale to Issuer -3,542 $35.01
2026-08-31 Xichen Lin Chief Scientific Officer & GM of Structure Shanghai Derivative Exercise and Sale -17,817 --
2026-08-31 Xichen Lin Chief Scientific Officer & GM of Structure Shanghai Derivative Exercise and Sale -5,939 $45.86–47.83
2026-08-17 Xichen Lin Chief Scientific Officer & GM of Structure Shanghai Derivative Exercise and Sale -11,817 --
2026-08-17 Xichen Lin Chief Scientific Officer & GM of Structure Shanghai Derivative Exercise and Sale -3,939 $53.13–55.05
2026-08-05 John Berrios -- Other Acquisition +140,766 --
2026-08-05 John Berrios -- Other Derivative Acquisition +174,612 $17.54
2026-08-03 Xichen Lin Chief Scientific Officer & GM of Structure Shanghai Derivative Exercise and Sale -11,817 --
2026-08-03 Xichen Lin Chief Scientific Officer & GM of Structure Shanghai Derivative Exercise and Sale -3,939 $49.29–50.03
2026-07-13 Xichen Lin Chief Scientific Officer & GM of Structure Shanghai Other Acquisition +7,878 --
2026-07-13 Xichen Lin Chief Scientific Officer & GM of Structure Shanghai Open Market Disposition -7,878 $50.80–51.71
2026-07-13 Xichen Lin Chief Scientific Officer & GM of Structure Shanghai Derivative Exercise and Sale -23,634 --
2026-07-13 Xichen Lin Chief Scientific Officer & GM of Structure Shanghai Other Derivative Acquisition +7,878 --
2026-07-13 Xichen Lin Chief Scientific Officer & GM of Structure Shanghai Open Market Derivative Dispositi -7,878 --
2026-06-24 Xichen Lin Chief Scientific Officer & GM of Structure Shanghai Other Acquisition +7,878 --
2026-06-24 Xichen Lin Chief Scientific Officer & GM of Structure Shanghai Open Market Disposition -7,878 $49.08
2026-06-24 Xichen Lin Chief Scientific Officer & GM of Structure Shanghai Derivative Exercise and Sale -23,634 --

Form 4 filings, most recent per company. "Other Derivative Acquisition" rows are mostly RSU/option vesting, not open-market buying - the Type column says which.

Quote time 2026-11-20 19:30:06 · For reference only, not investment advice and not tailored to your situation.

Structure Therapeutics discussion 0 comments

Add a comment